Singapore Markets closed

Straits Times Index
3,257.18
-5.36(-0.16%)
S&P 500
4,027.81
+56.54(+1.42%)
Dow
32,717.60
+323.35(+1.00%)
Nasdaq
11,926.24
+210.16(+1.79%)
BTC-USD
28,671.53
+304.95(+1.08%)
CMC Crypto 200
623.05
+22.08(+3.67%)

VRTX Jan 2024 370.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

8.26

0.00

(0.00%)

As of 02:50PM EDT. Market open.

Motley Fool
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbuster drug on the horizon.
Zacks
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.47, marking a -1.88% move from the previous day.
Business Wire
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
BOSTON & ZUG, Switzerland, March 27, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).